- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04647838
Tepotinib in Solid Tumors Harboring MET Alterations
A Phase II Study of Tepotinib in Patients With Solid Cancers Harboring c-MET Amplification or Exon 14 Mutation Who Progressed After Standard Treatment for Advanced/Metastatic Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ki Hyeong Lee, M.D.
- Phone Number: +82432696015
- Email: kihlee@chungbuk.ac.kr
Study Contact Backup
- Name: Eun Joo Kang, M.D.
- Phone Number: +82226263061
- Email: kkangju11@naver.com
Study Locations
-
-
-
Cheonan, Korea, Republic of
- Recruiting
- Dankook University Hospital
-
Contact:
- Soon Il Lee
- Email: avnrt@hanmail.net
-
Daegu, Korea, Republic of
- Active, not recruiting
- Keimyung University Dongsan Hospital
-
Daejeon, Korea, Republic of
- Active, not recruiting
- Konyang University Hospital
-
Goyang-si, Korea, Republic of
- Active, not recruiting
- National Cancer Center
-
Hwaseong-si, Korea, Republic of
- Active, not recruiting
- Hallym University Dongtan Sacred Heart Hospital
-
Incheon, Korea, Republic of
- Active, not recruiting
- Gachon University Gil Medical Center
-
Incheon, Korea, Republic of
- Active, not recruiting
- The Catholic University of Korea Incheon St. Marry Hospital
-
Jinju, Korea, Republic of
- Active, not recruiting
- Gyeongsang National University Hospital
-
Pusan, Korea, Republic of
- Active, not recruiting
- Inje University Haeundae Pain Hospital
-
Pusan, Korea, Republic of
- Active, not recruiting
- Kosin University Gaspel Hospital
-
Seongnam-si, Korea, Republic of
- Recruiting
- Seoul National University Bundang Hospital
-
Contact:
- Yu Jeong Kim
- Email: cong1005@gmail.com
-
Seoul, Korea, Republic of
- Active, not recruiting
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Recruiting
- Korea University Anam Hospital
-
Contact:
- Yun Ji Choe
- Email: yj_choi@korea.ac.kr
-
Seoul, Korea, Republic of
- Active, not recruiting
- Gangnam Severance Hospital
-
Seoul, Korea, Republic of
- Active, not recruiting
- Chungang University Hospital
-
Seoul, Korea, Republic of
- Active, not recruiting
- Inje University Sanggye Paik Hospital
-
Seoul, Korea, Republic of
- Active, not recruiting
- Korea University Guro Hospital
-
Seoul, Korea, Republic of
- Active, not recruiting
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Active, not recruiting
- Severance Hospital
-
Yangsan, Korea, Republic of
- Active, not recruiting
- Pusan National University Yangsan Hospital
-
-
Chonnam
-
Hwasun, Chonnam, Korea, Republic of
- Active, not recruiting
- Chonnam National University Hwasun Hospital
-
-
Chungcheongbuk-do
-
Cheongju-si, Chungcheongbuk-do, Korea, Republic of, 28644
- Active, not recruiting
- Chungbuk National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers)
- Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies
- Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers
- A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable).
- Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (≥6.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry.
- Male or female, 19 years of age or older
- Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment
- Life expectancy judged by the Investigator of at least 3 months
Exclusion Criteria:
1. Eligibility criteria:
- Histologically or cytologically confirmed solid cancers (NSCLC, gastric cancer, colorectal cancer, breast cancer, hepatocellular cancer, head and neck cancer, RCC and other solid cancers)
- Subjects who are not eligible for surgical and/or local-regional therapies or who have progressive disease (PD) after surgical and/or local-regional therapies
- Subjects who have disease progression or are intolerant to the prior standard treatment for advanced solid cancers
- A tumor biopsy (excluding fine needle aspiration and cytology samples) is required for determining MET status (a fresh pretreatment tumor biopsy is recommended but archived tumor sample is acceptable).
- Patients with MET exon 14 skipping mutation detected by NGS method and c-MET copy number gain (≥6.0) in the archival or fresh tumor tissue specimen identified in K-MASTER panel. All genetic findings must be reviewed by the study Molecular Steering Committee, prior to study entry.
- Male or female, 19 years of age or older
- Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST v 1.1). The target lesion that has received previous local therapy should not be considered as measurable unless clear progression has been documented since the therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Signed and dated informed consent indicating that the subject has been informed of all the pertinent aspects of the trial prior to enrollment
- Life expectancy judged by the Investigator of at least 3 months
2. Exclusion criteria
- Prior treatment with any agent targeting the HGF/c-MET pathway
- Prior EGFR therapy for EGFR activating mutant NSCLC
- Patients who received local treatment within 4 weeks prior to the first administration of tepotinib (e.g., major surgery, radiation therapy, hepatic arterial embolization, transcatheter arterial chemoembolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation). NOTE: palliative radiotherapy should be completed at least 7 days prior to the first administration of the tepotinib.
- Prior history of organ transplant
- Laboratory index at screening(refer to protocol)
- Past or current history of neoplasm other than current cancer, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, node-negative thyroid cancer or other cancer curatively treated and with no evidence of disease for at least 3 years
- Known central nervous system (CNS) or brain metastasis that is either symptomatic or untreated
- Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested products
- Clinically significant gastrointestinal bleeding within 4 weeks prior to the first administration of tepotinib.
- Impaired cardiac function(refer to protocol)
- Hypertension uncontrolled by standard therapies (not stabilized to ≤ 150/90 mmHg)
- Subject with a family history of long QT syndrome or who take any agent that is known to prolong QT/QTc interval or with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval > 450 msec)
- Known human immunodeficiency virus (HIV) infection
- Subjects who were diagnosed with acute pancreatitis and/or chronic pancreatitis by related symptoms or imaging study.
- Known or suspected drug hypersensitivity to any ingredients of tepotinib
- Female subjects who are pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug. A highly effective method of contraception is defined as having a low failure rate (< 1% per year) when used consistently and correctly.
- Concurrent treatment with anti-cancer therapy
- Substance abuse, other acute or chronic medical or psychiatric condition that may increase the risk associated with trial participation in the opinion of the Investigator
- Participation in another interventional clinical trial within 28 days prior to the first administration of tepotinib or within a time period that is less than the cycle length for the investigational treatment (whichever is shorter), or if the subject has any AE caused by the investigational treatment that has not recovered to Grade 0-1
- Previous anticancer treatment-related toxicities not recovered to baseline or Grade 1 (except alopecia) prior to administratin of tepotinib
- Subjects with any concurrent medical condition or disease that will potentially compromise the conduct of the study at the discretion of the Investigators
- Clinically significant third space fluid accumulation (despite the use of diuretics), e.g., uncontrolled pleural effusion or ascites
- Uncontrolled venous or arterial thromboembolism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NSCLC
Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
|
Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
Other Names:
|
Experimental: Other cancers
Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
|
Tepotinib 500mg (2 tablets of 250mg) per day D1-21 orally, once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rates (RECIST1.1)
Time Frame: Baseline up to 20 months
|
Objective response will be determined according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by investigator. Objective response is defined as either a confirmed complete response (CR) or partial response (PR) from first administration of trial treatment to first observation of progressive disease (PD). CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD is defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. |
Baseline up to 20 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Baseline until death, assessed up to 20 months
|
Overall survival is defined as the time (in months) from first trial treatment administration to the date of death.
|
Baseline until death, assessed up to 20 months
|
Progression free survival
Time Frame: Baseline until PD or death within 84 days of last tumor assessment; assessed up to 20 months
|
Progression free survival as assessed by investigators is defined as the time (in months) from the first administration of trial treatment to the date of the first documentation of PD (based on independent review) or death due to any cause within 84 days of the last tumor assessment, whichever occurs first
|
Baseline until PD or death within 84 days of last tumor assessment; assessed up to 20 months
|
Disease control rate
Time Frame: Baseline up to 20 months
|
Objective disease control is defined as either a confirmed CR or PR, or stable disease (SD) lasting at least 12 weeks (84 days) as assessed by investigator.
CR: Disappearance of all evidence of target and non-target lesions.
|
Baseline up to 20 months
|
Toxicity and drug compliance
Time Frame: From the first dose of study drug administration until 33 days after the last dose of study drug administration, assessed up to 20 Months
|
This outcome measure will be presented as the percentage of subjects with any adverse event (AE).
Percentages are calculated using total number of subjects per treatment cohort as the denominator.
|
From the first dose of study drug administration until 33 days after the last dose of study drug administration, assessed up to 20 Months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Ki Hyeong Lee, M.D., Chungbuk National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KM08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on Tepotinib
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...Completed
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyCompletedCarcinoma, HepatocellularChina, Taiwan, Korea, Republic of
-
M.D. Anderson Cancer CenterWithdrawn
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompleted
-
Hallym University Medical CenterRecruitingGastric Cancer | Gastroesophageal-junction CancerKorea, Republic of
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Criterium, Inc.EMD Serono Research & Development Institute, Inc.TerminatedAdvanced Non-Small Cell Lung Cancer With MET MutationsUnited States
-
EMD SeronoMerck KGaA, Darmstadt, GermanyCompletedPatients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is AvailableUnited States